Pliant Therapeutics Launches New $50 Million ATM Program

The latest announcement is out from Pliant Therapeutics ( (PLRX) ).

On March 30, 2026, Pliant Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program, allowing the company to sell up to $50 million of its common stock from time to time through the designated sales agent. This move followed the March 27, 2026 termination of its prior 2021 Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., under which no shares had been sold and no termination penalties applied, signaling a shift in Pliant’s capital-raising arrangements without immediate dilution from the older facility.

The most recent analyst rating on (PLRX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.

Spark’s Take on PLRX Stock

According to Spark, TipRanks’ AI Analyst, PLRX is a Neutral.

The score is primarily held back by weak financial performance—ongoing losses, consistent negative free cash flow, and a shrinking equity cushion. Technicals provide some support via improving short-term momentum, but longer-term trend signals remain soft, and valuation is constrained by negative earnings and no stated dividend yield.

To see Spark’s full report on PLRX stock, click here.

More about Pliant Therapeutics

Pliant Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies, primarily using small molecules, for the treatment of fibrotic diseases and other serious conditions. The company operates within the life sciences and healthcare sector, targeting unmet medical needs through clinical-stage drug development and related research activities.

Average Trading Volume: 787,489

Technical Sentiment Signal: Strong Sell

Current Market Cap: $72.44M

Learn more about PLRX stock on TipRanks’ Stock Analysis page.